SEC Comment Letter 0000000000-25-002673 to Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc.
Date: March 11, 2025 · CIK: 0001867096 · Accession: 0000000000-25-002673
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285597
Letter
Re: Xeris Biopharma Holdings, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285597 Dear John P. Shannon:
March 11, 2025
John P. Shannon Director and Chief Executive Officer Xeris Biopharma Holdings, Inc. 1375 West Fulton Street, Suite 1300 Chicago, IL 60607
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Joe Theis, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 11, 2025 John P. Shannon Director and Chief Executive Officer Xeris Biopharma Holdings, Inc. 1375 West Fulton Street, Suite 1300 Chicago, IL 60607 Re: Xeris Biopharma Holdings, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285597 Dear John P. Shannon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joe Theis, Esq. </TEXT> </DOCUMENT>